Book early and save up to $400

3rd Annual

Cancer Vaccines & Active Immunotherapeutics Summit

Approaches to Optimize Immune Response, Enhance Clinical Development & Drive Commercial Performance

26th – 28th June 2012, Boston

Benefits of attending

- Hear case studies on a **diverse range of immunomodulators and adjuvants** which **mediate meaningful anti-tumor clinical responses**
- Discover how to **enhance the potency** of your cancer vaccine by **combining it with other types of therapy**
- Discuss how to **design clinical studies** to maximize the potential of cancer immunotherapeutic candidates and **improve patient response** to immunotherapy by **selecting patients that will benefit**
- Get advice from the FDA on how to **manage regulatory obstacles** to ensure successful cancer vaccine development
- Find out **how to use biomarkers to predict the efficacy of your cancer immunotherapeutic**
- Overcome challenges faced during development of cancer vaccines that **target alternate routes of immunization**
- **Implement an evidence-based medicine approach** to ensure that your cancer immunotherapeutic demonstrates **value, affordability and a compelling clinical risk to benefit balance**

Workshops: 26th June 2012

A) Practices and Strategies to Overcome Challenges Associated with Manufacturing and Characterization of Cellular Immunotherapy Products
Scott Burger, Principal, Advanced Cell & Gene Therapy

B) How can we Monitor Patients Consistently: Overcoming Challenges in Monitoring the Immune Response
Sylvia Janetzki, President, ZellNet Consulting

"Outstanding…Excellent presentations, variety, very good organization, great networking sessions. Thanks for preparing and please repeat next year!"
GlaxoSmithKline

"High quality speakers, high content presentations and lots of opportunities for networking"
Pfizer

20 expert speakers including

Axel Hoos
VP, Oncology R&D, DPU Head, Combination Therapies
GSK

Peter Bross
Medical Review Officer, Office of Cellular, Tissue & Gene Therapy
FDA

Harpreet Singh
Co-Founder & CSO
Immatics Biotechnologies

Oliver Wilbert
Senior Director Immunotherapies
Merck Serono

Reiner Laus
President & CEO
BN ImmunoTherapeutics

Martin "Mac" Cheever
Principal Investigator: Cancer Immunotherapy Trials Network & Member
Fred Hutchinson Cancer Research Centre

Andres Salazar
President & CEO
Oncovir

Ramy Ibrahim
Senior Medical Director, Oncology, Clinical Development
MedImmune

Jeffrey Schlom
Chief, Laboratory of Tumor Immunology & Biology
NCI

Marc Mansour
COO & CSO
Immunovaccine

Tel: +1 212 537 5898 **Fax:** +1 212 537 5898 **Email:** info@hansonwade.com
www.cancervaccines-meeting.com

hansonwade

Benefits of attending

Are you working to develop blockbuster anti-cancer drugs?

You choose to work in the cancer vaccine and active immunotherapeutic sector because of the high potential to develop effective therapies for cancer patients. But many drugs are failing to demonstrate great enough efficacy to progress through clinical development. **How can you release the full commercial potential of your drug and ensure it gets to market?**

With a greater focus on combination approaches, novel immunomodulation strategies and more opportunities for open discussion and networking, the **3rd Annual Cancer Vaccines & Active Immunotherapeutics Summit** will provide cutting edge case studies that will guide you through every step of cancer immunotherapy development.

If you want to develop cancer vaccines and immunotherapeutics with huge potential for successfully treating patients, attend this meeting. Key opinion leaders from **GSK, Merck Serono, Immatics Biotechnologies, BN ImmunoTherapeutics** and many more will show you how.

1. **GSK, Merck Serono** and the **NCI** will explore how they are using combination approaches to enhance the potency of their cancer vaccines
2. Gain valuable insights into how **Oncovir, Genomics Institute of the Novartis Research Foundation, Celldex Therapeutics, Dana Farber/Harvard Cancer Center** and **BN ImmunoTherapeutics** are utilizing novel adjuvants and immunomodulators to generate a comprehensive immune response
3. Learn how to adopt an evidence-based medicine approach which demonstrates the comparative effectiveness of your therapeutic in relation to current standards of care with the **Blue Cross Blue Shield Association** and **AstraZeneca**
4. Understand the **FDA's** perspective on how to overcome regulatory obstacles to ensure effective cancer vaccine clinical development
5. The **Fred Hutchinson Cancer Research Center** will discuss how they are prioritizing various cancer immunotherapeutics which have high potential for treating cancer
6. Hear strategies to enhance clinical trial design and understand when to consider biomarker research and immunomonitoring during clinical development with **MedImmune, Immunovaccine** and **DanDrit Biotech**
7. **Immatics Biotechnologies** will show you how they are using a biomarker-guided approach to clinical development to identify mechanisms of action and resistance, and to predict the responders to immunotherapy
8. Find out how **Vaccinogen** is overcoming challenges faced during manufacturing by ensuring controlled and consistent sourcing of the cellular raw material

Who should attend?

This meeting has been designed to provide **cutting edge insights into how drug developers are developing and commercializing cancer vaccines and active immunotherapeutics**. It's also a fantastic occasion for companies currently focused on wider cancer immunotherapy to explore new opportunities, and will provide the latest industry knowledge for:

- **Cancer vaccine experts**
- **Combination therapy & cancer immunotherapy researchers**
- **CEOs, CSOs, CMOs & COOs**
- **Oncology, immunology & vaccine leaders**
- **Medical directors**
- **Clinical oncologists**
- **Heads of BD**
- **Regulators**
- **Consultants**

LinkedIn Search groups for: **Commercializing Cancer Vaccines Forum** to join the online community.

Hear what attendees said about our other Cancer Vaccine meetings:

"This was a highly focused meeting that reviewed many elements of relevance to project teams and executives advancing cancer immunotherapy"

Advanced Immune Therapeutics

"A truly stellar collection of speakers. Should become the pre-eminent cancer vaccine conference melding scientific, clinical and commercial issues"

Defined Health

"Very useful to get overview of the challenges in the field"

Oncothyreon

"Very stimulating – one of the best conferences this year"

Vaxigenix

"Great opportunity to hear what other companies are doing"

Sequenta

"Very helpful to meet potential collaborators"

Immune Design

Tel: +1 212 537 5898 **Fax:** +1 212 537 5898 **Email:** info@hansonwade.com

www.cancervaccines-meeting.com

hansonwade

3rd Annual Cancer Vaccines & Active Immunotherapeutics Summit | Boston | 26th – 28th June 2012

Keynote Session | Panel Session | Networking Session

Day 1 — 27th June 2012

08.00 **Registration, Coffee & Networking**

08.55 **Chair's Opening Remarks**
Harpreet Singh, Co-Founder & CSO, Immatics Biotechnologies

09.00 **The Current Status of Cancer Vaccines and Active Immunotherapeutics: A Global Overview of the Field**
- Active immunotherapy (AI) is an emerging field comprising therapeutic cancer vaccines and immune modulators that complement current treatment options to fight cancer
- After a decade of limited success in clinical trials, approvals of the first AIs have changed the perspective on the field

Ramy Ibrahim, Senior Medical Director, Oncology Clinical Development, MedImmune

Optimizing the Effectiveness of Cancer Vaccines Using Combination Approaches

09.30 **Combination Therapies: The Next Generation of Treatment Modalities in Oncology**
- Combination therapies to deliver innovation
- Critical components and criteria for co-development
- A scientific, collaborative approach to combination therapy development

Axel Hoos, VP, Oncology R&D, DPU Head, Combination Therapies, GSK

10.00 **Enhancing the Potency of Cancer Vaccines by Using Combination Approaches**
- The importance of the appropriate patient population and clinical trial endpoint(s)
- Advances in understanding of the "epithelial-to-mesenchymal transition" (EMT) process of human carcinomas
- How EMT relates to tumor progression and metastasis offer unique potential for immune targeting of these processes

Jeffrey Schlom, Chief, Laboratory of Tumor Immunology & Biology, NCI

10.30 **Morning Refreshments & Speed Networking**

12.00 **Advances and Challenges in the Development of Novel Cancer Vaccines: An Update on L-BLP25, STIMUVAX**
- Off-the-shelf approaches in prostate and lung cancer with an update on the most advanced candidates in phase III
- Lessons learnt on therapeutic settings for active immunotherapies in oncology
- Fundamental issues and key success factors for active immunotherapy development

Oliver Wilbert, Senior Director Immunotherapies, Merck Serono

12.30 **Ipilimumab/PROSTVAC Combination: Early Clinical Trial Update**
- Combination of an immune checkpoint inhibitor (Ipilimumab) with Prostvac is safe
- Early evidence of clinical activity indicated by PSA responses and longer than predicted survival (median 3.4.4 months)

James Gulley, Head, Clinical Trials Group, Laboratory of Tumor Immunology & Biology, NCI

1.00 **PANEL DISCUSSION: When Should you Approach Other Companies for Collaboration during Development of Combination Therapies?**
- Determining whether co-development is an appropriate development option
- Co-develop from the beginning or during development?

Axel Hoos, VP, Oncology R&D, DPU Head, Combination Therapies, GSK & **Jeffrey Schlom**, Chief, Laboratory of Tumor Immunology & Biology, NCI

1.30 **Lunch & Networking**

Ensuring Effective Clinical Trial Design

2.45 **Case Study: Sipuleucel-T: An Autologous Cellular Immunotherapy for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer**
- Clinical safety and efficacy of Sipuleucel-T
- Linking immune response with clinical response

Robert Tyler, Medical Director, Dendreon

3.15 **Case Study: Clinical Development of DPX-Survivac, a Multi-Cancer Vaccine Targeting the Broadly Expressed Tumor Associated Antigen Survivin**
- Survivin is a TAA with uniform expression (rather than multi-focal) in a many solid tumors
- DPX-Survivac targeting Survivin is enhanced using the Depovax formulation
- Vaccine in combination with an immune modulator with the potential to suppress tumor induced regulatory T cells

Marc Mansour, COO & CSO, Immunovaccine

3.45 **Afternoon Refreshments & Networking**

4.15 **Current Challenges in Designing and Conducting Phase II Oncology Clinical Trials**
- Survival time, data complexity and costs are increasing and these drivers trigger changes in the way we design trials
- Exploring endpoints with a focus on progression free survival, randomization and regulatory hurdles
- Strategies to optimize protocols, achieve faster enrollment and shorten study timelines

Eric Leire, CEO, DanDrit Biotech

4.45 **PANEL DISCUSSION: How can we Change our Early-Stage Study Design for Cancer Immunotherapies?**
- Are combined phase I/II studies and adaptive designs adequate and should we be testing combinations in phase I?
- What are the benefits and risks of small randomized phase II studies, and what is the value of immunomonitoring and biomarker research in early clinical studies?

Ramy Ibrahim, Senior Medical Director, Oncology Clinical Development, MedImmune, **Eric Leire**, CEO, Dandrit Biotech & **Marc Mansour**, COO & CSO, Immunovaccine

Gaining Regulatory Approval

5.15 **FDA Update on Regulatory Considerations for Development of Therapeutic Cancer Vaccines**
- Regulation of cancer therapeutics in US including recent changes at CDER
- Clinical trials with therapeutic cancer vaccines: What have we learnt?
- Companion diagnostics: Challenges and opportunities of personalized medicine

Peter Bross, Medical Review Officer, Office of Cellular, Tissue & Gene Therapy, FDA

5.45 **Chair's Closing Remarks**

Tel: +1 212 537 5898 **Fax:** +1 212 537 5898 **Email:** info@hansonwade.com
www.cancervaccines-meeting.com

hansonwade

Keynote Session | Panel Session | Networking Session

Day 2 — 28th June 2012

08.00 **Registration, Coffee & Networking**

08.40 **Chair's Opening Remarks**
Vahe Bedian, Director, AstraZeneca

08.45 **Prioritization of Immunotherapy Opportunities and the Cancer Immunotherapy Trials Network (CITN)**
- A major barrier for developing effective immunotherapy is that invented immunotherapy agents with proven function and benefit to cancer patients are not broadly available for testing
- The CITN conducts early phase trials designed to achieve the optimal route to proof of concept, demonstration of patient benefit and regulatory approval
- Update on trials with anti-CD40, IL15, IL7, Flt3-Ligand and an IDO inhibitor

Martin "Mac" Cheever, Principal Investigator: Cancer Immunotherapy Trials Network & Member, Fred Hutchinson Cancer Research Center

Utilizing Biomarkers in Clinical Development

09.15 **Biomarker-Guided Development of Novel Renal and Colorectal Cancer Multi-Peptide Vaccines: From Discovery to Phase III**
- Discovery biomarkers: Naturally presented tumor-associated peptides
- Mechanism-of-action biomarkers: T-cell response monitoring and clinical benefit associations
- Prognostic/predictive biomarkers: Novel cellular and serum biomarkers

Harpreet Singh, Co-Founder & CSO, Immatics Biotechnologies

Eliciting a Stronger Immune Response

09.45 **Optimizing the Use of Immunomodulators: A Poly-ICLC (Hiltonol®) Case Study**
- Background and preclinical study results
- Hiltonol as a PAMP and a viral mimic: When properly combined with antigen it can mimic a live-virus-vaccine and generate a comprehensive adaptive immune response
- Ongoing clinical cancer and HIV vaccine trials and emerging clues to optimal use

Andres Salazar, Chairman, CEO, & Scientific Director, Oncovir

10.15 **Morning Refreshments & Networking**

10.45 **Using New Technologies to Create a More Powerful Immune Response**
- Breaking tolerance with recombiant proteins encoding un-natural aminoacids
- Generating robust immune responses with novel TLR agonists

Teresa Ramirez-Montagut, Research Investigator, Cancer Vaccine Initiative, Genomics Institute of the Novartis Research Foundation

11.15 **Approaches to Improving Anti-Tumor Immunity**
- Targeted antigen delivery to DCs in humans
- Enhancing T cell responses with CD27 co-stimulation
- Other combination opportunities for enhancing immunity to cancer

Tibor Keler, CSO, Celldex Therapeutics

11.45 **Assessing the Immunologic and Clinical Efficacy of Dendritic Cell/Tumor Fusions as a Cancer Vaccine**
- Application of the cancer vaccine to multiple myeloma
- Update on results of dendritic cell tumor fusion vaccine
- Exploring the interaction of cancer vaccines and PD1 blockade

David Avigan, Active Staff, Hematology-Oncology, Beth Israel Deaconess Medical Center & Associate Professor, Dana Farber/Harvard Cancer Centre

12.15 **Lunch & Networking**

1.15 **Active Immunotherapy of Cancer with Recombinant Poxviral Vaccines**
- Vaccines as a foundation for therapy
- Demonstrating a clear survival benefit and a favorable safety profile compared with other treatment options

Reiner Laus, President & CEO, BN ImmunoTherapeutics

An Evidence-Based Medicine Approach

1.45 **How Good is the Evidence? View from the Blue Cross Blue Shield Technology Evaluation Center**
- Strength of evidence to assess outcomes
- Ensuring value and affordability

Naomi Aronson, Executive Director of the Technology Evaluation Center, Blue Cross Blue Shield Association

2.15 **PANEL DISCUSSION: Comparing Cancer Vaccine Treatment with Traditional Cancer Therapy**
- A compelling clinical risk:benefit balance
- Handling changing standards of care during clinical trials

Naomi Aronson, Executive Director of the Technology Evaluation Center, Blue Cross Blue Shield Association & **Vahe Bedian**, Director, AstraZeneca

2.45 **Afternoon Refreshments & Networking**

Manufacturing Considerations & Novel Routes of Immunization

3.15 **Controlled and Consistent Sourcing of the Cellular Raw Material: Overcoming Challenges faced during Manufacturing**
- Aseptic manufacturing resulting in a sterile, live cell drug product
- How to retain cell potency

Michael Hanna, Founder, Chairman & CSO, Vaccinogen

3.45 **Oral Administration: Moving from Infectious Disease to Cancer Applications**
- Oral immunization is the best, if not only way, to generate good immunity in the intestinal mucosa
- Oil-based formulations present antigens well to immune system and are well accepted by the gastro-intestinal tract
- New technology for encapsulation of protein in oil can capitalize on these advantages

Roger New, Founding Director & Chief Scientist, Kancer

4.15 **Chair's Closing Remarks**

Workshop A: Practices and Strategies to Overcome Challenges Associated with Manufacturing and Characterization of Cellular Immunotherapy Products

Date: 26th June 2012
Time: 10am – 1pm

Manufacturing and testing cell-based cancer immunotherapy products presents particular challenges, due to their biologic nature and complex immunologic functions. Establishing **cost-effective, commercial-scale manufacturing** requires a significant development effort, an **understanding of cellular raw material and product** and employing tools of cell therapy bioprocessing.

Attendees will explore and discuss:

- **Process development priorities at different stages** in preclinical and clinical development
- Process scale and throughput: Considerations for **autologous and allogeneic products**
- Characterization testing: Focusing on **safety, purity, identity and potency**
- How to **build and refine the product characterization profile**
- How to **control and define cellular raw material, managing inter-individual variability**
- Exploring different cell processing technologies including **cell isolation, expansion, washing, storage** and **closed-system cell processing: When and how do you introduce automation?**
- Conducting **stability and comparability studies:** Options for **extending shelf-life** and **bridging manufacturing process changes**

Participants will leave this workshop with the knowledge to apply different **practices and strategies to overcome the challenges of these living biologic products** in order to ensure successful manufacturing and characterization of cell-based vaccines and immunotherapy products for cancer.

Workshop leader

Scott Burger
Principal
Advanced Cell & Gene Therapy

Scott Burger is the principal of Advanced Cell & Gene Therapy, a consulting firm specializing in development and commercialization of cell, gene and tissue-based products for immunotherapy and regenerative medicine. Dr. Burger works with clients in industry and academic centers worldwide, leveraging over 20 years of industry and academic experience to provide expert guidance in technology evaluation and due diligence, GMP/GTP manufacturing and characterization, process development, facility design, regulatory affairs and strategic analysis. He received his M.D. from the University of Pennsylvania School of Medicine, and completed postgraduate training in Laboratory Medicine, and a fellowship in Transfusion Medicine, at Washington University in St. Louis. Dr. Burger served as medical director of the Cell Therapy Clinical Laboratory and Molecular and Cellular Therapeutics Facility at University of Minnesota, and was Vice-President for Research and Development at Merix Bioscience, a dendritic cell immunotherapy company.

Workshop B: How can we Monitor Patients Consistently: Overcoming Challenges in Monitoring the Immune Response

Date: 26th June 2012
Time: 2pm – 5pm

While monitoring immune responses plays an increasing role in clinical immunotherapeutic trials, various challenges accompany related approaches. The **integrity of the patient sample to be monitored is of outmost importance** since **only a fully functional sample can provide reliable results**. Evolving strategies for obtaining clinical specimen, with focus on peripheral blood mononuclear cells, will be presented. Attendees will leave with an understanding of:

- **Strategies to minimize the loss of functionality for samples with delayed processing (>8 hours)**
- **Shipping and storage of samples before processing**
- **Freezing, thawing and recovery techniques**
- **Strategies for multi-center trials**

Another monitoring challenge is the establishment of reliable and precise assays that provide accurate data, a challenge for many cellular immune assays that have no or very limited gold standards available that prove the accuracy of an applied assay. **Strategies to overcome these challenges will be presented** for further discussion, **including reference samples with a defined number of antigen-specific T-cells, assay harmonization strategies, internal and external controls.**

Active participation by attendees and discussion is strongly encouraged.

Workshop leader

Sylvia Janetzki
President
ZellNet Consulting

The focus of Sylvia's work during the past 16 years has been immune monitoring approaches for clinical studies with specific focus on the Elispot assay. Her work has also led her to a tight collaboration with the Cancer Immunotherapy Consortium (CIC/CRI), for which she initiated and lead a proficiency panel program addressing different assays like Elispot, Multimer staining, ICS, Luminex and others. This program with more than 100 laboratories from around the world aims at offering an external validation program and enhancing assay harmonization. She received her MD from Humboldt University, Berlin and her post-doctoral training in Immunology from Fordham University.

Media partners

PharmaVOICE
espicom BUSINESS INTELLIGENCE
BENTHAM SCIENCE PUBLISHERS LTD.
Lifescience Global
humanVACCINES & IMMUNOTHERAPEUTICS
drug discovery world DDW Turning science into business
HPV Today

Tel: +1 212 537 5898 **Fax:** +1 212 537 5898 **Email:** info@hansonwade.com
www.cancervaccines-meeting.com

hansonwade

Speakers

Naomi Aronson
Executive Director, Technology Evaluation Center, **Blue Cross Blue Shield Association**

Naomi Aronson is the Executive Director of the Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Dr. Aronson has overseen TEC's development as a nationally recognized technology assessment program.

David Avigan
Active Staff, Hematology-Oncology & Associate Professor, **Beth Israel Deaconess Medical Center & Dana Farber/ Harvard Cancer Centre**

Dr. Avigan is an Associate Professor of Medicine at Harvard Medical School. He has established a translational research program for cancer vaccines at BIDMC as part of the Dana Farber Harvard Cancer Center.

Vahe Bedian
Director
AstraZeneca

At AstraZeneca, a major area of research interest for Vahe has been immune enhancement approaches for cancer therapy, including T-cell co-stimulation, enhancement of antigen presentation, and modulation of immunosuppressive mechanisms.

Peter Bross
Medical Review Officer, Office of Cellular, Tissue & Gene Therapy, **FDA**

Dr. Bross is a clinical oncology team leader in the FDA Center for Biological Evaluation and Research. He has expertise in the design and analysis of clinical oncology trials of cellular, tissue and gene therapies, especially cancer vaccines.

Martin "Mac" Cheever
Principal Investigator: Cancer Immunotherapy Trials Network & Member, **Fred Hutchinson Cancer Research Centre**

Mac Cheever is Principal Investigator of the Cancer Immunotherapy Trials Network (CITN), member and Director of Solid Tumor Research, Fred Hutchinson Cancer Research Center and Professor of Medicine, University of Washington.

James Gulley
Head, Clinical Trials Group, Laboratory of Tumor Immunology & Biology, **NCI**

Dr. Gulley is a Senior Investigator and Deputy Chief of the Laboratory of Tumor Immunology and Biology and directs a clinical trials group within the NCI focusing on cancer immunotherapy.

Michael Hanna
Founder, Chairman & CSO
Vaccinogen

Dr. Michael Hanna is founder of Vaccinogen and the discoverer and developer of OncoVAX® an autologous vaccine designed to provoke a specific immune response against cancer cells.

Axel Hoos
VP, Oncology R&D, DPU Head, Combination Therapies
GSK

Dr. Hoos is VP, Oncology R&D at GSK, where he directs clinical and translational research on molecular mechanisms of cancer and tumor-host interactions for rational combination of therapeutic modalities.

Ramy Ibrahim
Senior Medical Director, Oncology, Clinical Development
MedImmune

Dr Ibrahim is currently Senior Medical Director within Oncology Clinical Development at MedImmune. Ramy is also part of the CIC scientific meeting steering committee.

Tibor Keler
CSO
Celldex Therapeutics

Tibor Keler is currently Senior VP and CSO of Celldex Therapeutics, a company he helped found and spin out from Medarex in 2005. He had spent 12 years at Medarex overseeing research and pre-clinical development activities.

Reiner Laus
President & CEO
BN ImmunoTherapeutics

Dr. Laus is founding CEO and President of BN ImmunoTherapeutics, formed as a member of the Bavarian Nordic group in 2005. Prior to this, he was VP of R&D at Dendreon Corporation.

Eric Leire
CEO
DanDrit Biotech

Dr. Leire is the CEO of DanDrit Biotech, a Copenhagen-based biotech company developing a MCV®, a cancer vaccine for advanced colorectal cancer patients. MCV® is currently evaluated in a multicenter randomized Phase IIb clinical trial.

Marc Mansour
COO & CSO
Immunovaccine

Marc Mansour has led the development of the company's unique vaccine adjuvanting platform, bringing it from concept to clinical application. He oversees preclinical research, clinical activities, and the company's patent strategy.

Roger New
Founding Director & Chief Scientist
Kancer

Roger New's research has centred on the use of drug delivery systems to improve the therapy of disease. He is Co-founder and Executive Director of Proxima Concepts. Roger New studied chemistry at Oxford and obtained a PhD in immunology at St Mary's Hospital, London.

Teresa Ramirez-Montagut
Research Investigator, Cancer Vaccine Initiative, **Genomics Institute of the Novartis Research Foundation**

Teresa has more than 15 years of experience in the field of tumor immunology including vaccination/ immunomodulation strategies, preclinical modeling and preclinical/ clinical immunomonitoring.

Andres Salazar
President & CEO
Oncovir

Dr. Salazar is Chairman, CEO, Scientific Director and co-founder of Oncovir, Inc, a small pharmaceutical company developing the potent immunomodulator, Hiltonol® (Poly-ICLC). Dr. Salazar was formerly Professor of Neurology at the Uniformed Services University in Bethesda.

Jeffrey Schlom
Chief, Laboratory of Tumor Immunology & Biology
NCI

Dr. Schlom is Chief of the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute. He emphasizes the use of cancer vaccines as a monotherapy and in combination with other therapeutic modalities.

Harpreet Singh
Co-Founder & CSO
Immatics Biotechnologies

Dr. Singh is Managing Director, CSO and co-founder of Immatics and is dedicated to the translation of science into highly innovative cancer immunotherapeutics. Some of his specialties are translational research, clinical immunomonitoring in multi-center trials and biomarkers.

Robert Tyler
Medical Director
Dendreon

Robert Tyler is a Medical director at Dendreon specializing in sipuleucel-T in early stage prostate cancer and is the medical lead for PROCEED. Previous to Dendreon, Robert worked at Centocor Orthobiotech immunology and Atrix Laboratories and the development of Eligard.

Oliver Wilbert
Senior Director Immunotherapies
Merck Serono

Dr. Wilbert joined Merck in 1996. Since 2007 he has been the global lead for the phase III project STIMUVAX. Since 2010 he has headed up the immunotherapy project leads at Merck Serono.

Sponsorship opportunities

Miles Harley

If your organization needs to raise profile, promote products and services or develop new partnership opportunities in the cancer vaccine and active immunotherapeutics sector, contact:

tel: +44 (0)20 3141 8700
email: miles.harley@hansonwade.com

Working with Hanson Wade

When you work with Hanson Wade you work with a partner focused on your success. Your investment in both time and money needs to generate a return.

Our clients want that too and that's why they work with us. They want to reach a targeted audience and eliminate wastage from their marketing activities. They work with us because we deliver results. We're proud of this fact.

Our research identifies ground breaking issues and allows you to influence industry thinking at an early stage. Our expertise is recognised and respected by the industry. And our events are focused, leading edge and attended by people looking for knowledge before making decisions.

Attendee breakdown

Attendee breakdown at the last meeting



Seniority breakdown at the last meeting



Speaking organizations

VACCINOGEN Turning Cancer On Itself™ · National Cancer Institute · immatics · Dendreon · Oncovir · BlueCross BlueShield Association · MERCK SERONO · MedImmune · IMV Immunovaccine · DanDrit Biotech · AstraZeneca · Celldex therapeutics · Fred Hutchinson Cancer Research Center · Genomics Institute of the Novartis Research Foundation · FDA · gsk GlaxoSmithKline · Bavarian Nordic · Dana-Farber Cancer Institute · Kancer

Sponsor testimonials

"These are relevant, well organized events with a comprehensive speaker panel featuring the key thought leaders in the industry, and an intelligent, forward thinking and discussion-provoking agenda"

QIAGEN

"First class meeting - an incredible opportunity to meet directly with a broad range of decision makers in this growing field"

Quanta BioDesign

3rd Annual Cancer Vaccines & Active Immunotherapeutics Summit	Boston	26th – 28th June 2012	Priority Code: MKT

Register

Online: www.cancervaccines-meeting.com
Tel: +1 212 537 5898
Fax: +1 212 537 5898
Email: info@hansonwade.com

Mail:
Hanson Wade
Charter House
13-15 Carteret St
London, SW1H 9DJ

Team discounts

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Venue and accommodation

Venue
Sheraton Boston, 39 Dalton Street, Boston, MA 02199, USA
Tel: +1 617 236 2000

Accommodation
Accommodation is not included in your fee. You will be sent accommodation options upon registration.

Purchase audio presentations

If you are unable to attend the meeting in person or would like documentation in addition to your attendance you may purchase the audio recordings of the speaker presentations for **$799**.

These will be sent to you on CD rom with all available presentation slides within 10 days of the meeting. Audio orders can only be processed on receipt of credit card details.

Event prices

Package	Register and pay before Friday 13th April*	Register and pay before and Friday 11th May*	Standard Price*
☐ Conference + 2 workshops	$3097 (SAVE $400)	$3197 (SAVE $300)	$3297 (SAVE $200)
☐ Conference + 1 workshop	$2598 (SAVE $300)	$2698 (SAVE $200)	$2898
☐ Conference	$2099 (SAVE $200)	$2199 (SAVE $100)	$2299
☐ Half day workshop	$599	$599	$599

Please select your choice of workshop: Workshop A ☐ Workshop B ☐

A 40% discount is available for academics and not for profit organizations, please email **info@hansonwade.com** for more information or to register.

*All discount offers (including team discounts) require payment at the time of registration to receive any discount. 'Early Bird' discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.

Delegate details

Title: Forename: Surname:

Job Title: Company/Organization:

Email: Direct Manager:

Address:

Postcode:

Country: Direct Telephone:

Direct Fax: Mobile:

Switchboard: Signature: Date:

Payment details

Number of delegates ☐ Amount: $ _____ Conference Documentation ☐ Credit Card: ☐ Visa ☐ Mastercard ☐ Amex ☐

Card No: ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐ Valid from: ☐☐/☐☐ Expiry Date: ☐☐/☐☐

Cardholders name:

Signature: Date:

Card billing address:

TERMS & CONDITIONS

Full payment is due on registration.Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities

Data Protection The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Charter House, 13-15 Carteret Street, London SW1H 9DJ

Code: 2274

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216

Tel: +1 212 537 5898 Fax: +1 212 537 5898 Email: info@hansonwade.com
www.cancervaccines-meeting.com

hansonwade